NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Benitec Biopharma Inc. BNTC
7 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
EPS · FY24
$-1.05
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-52.5%
Net margin · FY24
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2024 · full 7-year series below
Revenue
Net income
Per share
USD -1.05
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-52.5%
Return on equity, FY2024
ROE
Operating margin—
Net margin—
Return on assets-50.0%
Each USD of equity lost 52 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 99.6M
total assets, end of FY2024
Total assetsUSD 99.6M
EquityUSD 97.3M
CashUSD 97.7M
Current ratio54.67×
Equity funds 98% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
Revenue $B
·
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
Income tax $B
·
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EPS, diluted $
−1.05
−1.22
−14.12
−37.88
−3.23
−8.10
3.05
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−52.5
−91.7
−1268.6
−159.1
−91.8
−61.7
15.7
Shares out B
0.03
0.01
0.00
0.00
0.01
0.00
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed